SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings beat, first reported profit, and sharp growth in its AI-compute business are driving attention, with traders also reacting to ambitious forward revenue and spending commentary. Many are bullish and anticipate short covering, while others question the valuation, heavy capital expenditure, and whether the AI growth can justify expectations.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update, which raised its revenue outlook substantially and projected improved gross margins on stronger AI-platform demand, is driving attention. Many traders welcomed the update and speculated about short covering, while others questioned whether the gains would hold given the companys history and ongoing concerns about execution and profitability.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations, but softer fourth-quarter guidance and slowing revenue growth drove a sharp selloff, with traders also concerned about weaker advertising growth and execution. Bears see evidence of fading growth amid streaming competition, while bulls argue the profitable quarter makes the decline an overreaction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas upcoming quarterly results and Musks confirmation that Tesla and SpaceX have formed committees to explore a possible merger are driving attention. Traders debate whether merger prospects could support the stock or remain speculative, while others focus on earnings expectations and Teslas profitability; no deal has been agreed.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in volatile trading across AI infrastructure and neocloud stocks, with financing and debt concernsespecially spillover from CoreWeavedriving bearish debate. Bulls counter that AI compute demand remains strong and Nebius is better positioned than some peers, while traders watch broader tech spending and earnings for direction.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels steep pullback and volatile rebounds ahead of earnings are driving discussion, alongside JPMorgans move to Neutral and reports of potential foundry customers. Traders are split between optimism about a foundry turnaround and skepticism over execution, valuation and the dilutive effect of Intels large share offering.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff and continued underperformance versus other neocloud and data-center stocks dominate discussion, alongside broader worries about how AI-cloud providers will finance expansion. Co-CEO Daniel Roberts claim that IRENs data centers were built with cash and carry no asset-level debt reassured some traders, while others remain concerned about the stocks weakness and whether any rebound can hold.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported orders from Chinese tech firms for Nvidias export-compliant GPUs are fueling discussion of strong demand despite U.S. restrictions; traders also note Nvidia may be able to fulfill only a small share of the orders. The community is divided as the stocks muted reaction and recent weakness keep concerns about AI spending, financing risks, and the sustainability of the rally in focus.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares rallied as traders focused on the Phase 3 REGAL AML trial nearing its 80-event threshold, which triggers final analysis; the last disclosed count was 78. Bulls see the approaching milestone and the CEOs upbeat anniversary comments as reasons for optimism and speculate about a buyout, while skeptics note that no new results or deal have been confirmed and attribute the move to volatile trading.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo is drawing attention for sharp, high-beta swings after a steep pullback, with traders debating whether the weakness reflects broader pressure on AI and semiconductor stocks or company-specific concerns such as insider selling and valuation. Bulls point to continued AI data-center demand for its connectivity products and view the dip as a buying opportunity, while others remain cautious about volatility and execution risks in its optical expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immuneering Corp Appoints Andrew Gengos As CFO

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16...

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

Equity

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.


Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...

Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Neutral Sentiment

<ul class="summary-bullets"><li>The selloff follows the company's presentation of updated early-stage data for its pancreatic cancer drug, atebimetinib, at the ASCO 2026 Annual Meeting.</li><li>The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients.</li><li>Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.</li></ul> Shares of Immuneering Corporation (IMRX) fell sharply on Monday, dropping about 23%, after the company presented updated early-stage data for its pancreatic cancer drug atebimetinib at the ASCO 2026 Annual Meeting.Despite the positive results, the stock slipped following a recent run-up in the stock. The stock closed up 14% on the last trading day but is now on track to record its worst day since early January, if losses hold.<h2 class="st-heading-2">IMRX’s Trial Data</h2>The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients. That is more than double the 8.5-month historical average for the standard chemotherapy alone. Median progression-free survival was 8.3 months, with an objective response rate of 36% and a disease control rate of 82%. The drug was generally well tolerated, with no major new safety issues reported.Both overall survival and median progression-free survival help doctors understand how well a cancer treatment is working. Overall survival (OS) is the length of time from the start of treatment until a patient dies from any cause, while median progression-free survival (PFS) measures the time from the start of treatment until the cancer worsens or the patient dies.Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.CEO Ben Zeskind said the results strengthen the company’s belief that atebimetinib could meaningfully improve outcomes for pancreatic cancer patients.<h2 class="st-heading-2">How Did IMRX Retail Traders React?</h2>On Stocktwits, retail sentiment around IMRX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user attributed the stock drop to a “sell the news” event.<stembedurl>https://www.stocktwits.com/stockymon/message/655020849</stembedurl>Another user cheered the “good results” and expressed optimism for the stock touching $6/ share this month.<stembedurl>https://www.stocktwits.com/CEM97/message/655018031</stembedurl>According to data from Koyfin, all six analysts covering IMRX rate it ‘Buy’ or higher. The average 12-month price target on the stock is $17, representing a potential upside of about 195% from last closing price.<a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> has gained over 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivn-stock-surges-as-r2-nears-delivery-kickoff/cZ0WRzjRevO">RIVN Stock Surges For 8th Straight Day: Rivian’s Rival To Tesla Model Y Nears June 9 Delivery Kickoff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Immuneering logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.

Immuneering Corp

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.73
Prev Close	$3.66
Open	$3.70
Dividend Yield	0.00%
50-Day Moving Average	$4.51
Beta	1.38
Avg. Volume	702,519.94
PE Ratio	-3.55

52-Week High	$8.48
52-Week Low	$3.38
Market Capitalization	$236.79M
EPS (Annual)	-$1.27
Price to Book	1.24
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMRX Fundamentals